Korro Bio completed dosing for its KRRO-110 study in AATD, expects interim results in 2025, and has strong financial resources. Korro Bio, Inc. has completed dosing for the first two cohorts in its ...
STgen Bio will invest 110 billion won ($73.8 million) to expand its biopharmaceutical manufacturing facilities in Incheon, the company announced Friday. With the investment, STgen Bio will establish ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results